Less virulent Covid strain positively impacts numerous sectors

Financial markets have spent the last eighteen months looking over their shoulder for new and potentially more dangerous Covid variants. The arrival of the more transmissible Omicron in late November initially looked like it may herald what many had feared. Governments responded by putting in place restrictions and activity sagged. Yet despite soaring infection rates and a pick-up in hospitalisations, deaths have remained low. Investors interpreted this as the ‘market clearing event’ that facilitates the transition to a more normalised environment. Equity markets rebounded and made new all-time highs.

The minutes of the December Federal Reserve Board showed participants believed that higher inflation and a tight labour market could necessitate lifting short-term rates “sooner or at a faster pace than participants had earlier anticipated.” Officials also now expect to end the expansion of the Fed’s balance sheet in March. The practical impact of these moves is limited but the ‘signalling’ effect is more significant and has driven a sharp rotation out of ‘growth’ stocks into ‘value’. Despite the initial intra market volatility, monetary conditions are not about to dramatically tighten. Investors will, however, need to navigate the transition from a liquidity driven bull market to one driven by earnings. Volatility has increased and the recent sector rotation will likely continue. But with a strong underlying global economy and significantly negative real interest rates the equity bull market is intact.

The emerging consensus that Omicron, while more transmissible, is considerably less virulent positively impacted numerous sectors. Increased confidence in the economic outlook drove a recovery in cyclicals. Travel related stocks bounced strongly as confidence grew that the worst of any Covid disruption was behind us. We believe a more regular market is already factored into market expectations but unfortunately this will only become apparent with time. Even if conditions prove to be weaker than anticipated the company is more diversified than it has been in the past and the valuation attractive.

Capital at risk

The information provided does not constitute investment advice and is not an offer to invest in any SVM funds or any of the securities mentioned.  If you are unsure about the suitability of an investment please consult an authorised financial adviser.

Past performance is not a guide to future performance. All financial instruments involve a degree of risk. The value of your investments and the income from them can go down as well as up and you may not get back the amount originally invested.

The views and opinions expressed in the articles on this website belong to the authors and do not necessarily represent the views and opinions of other SVM Asset Management Ltd employees. Some of the information and data contained on this website has been obtained from external sources that we believe to be reliable but in no way are warranted by us as to their accuracy or completeness.  SVM does not accept any liability arising from any inaccuracy or omission in or the use of or reliance on the information on this website.

Users accessing this website from outside the United Kingdom do so at their own risk and should be aware that SVM may not have the appropriate regulatory permissions to offer its products to you.  SVM funds are not available to residents of the United States of America, residents within an area subject to its jurisdictions or United States Persons.

SVM Asset Management Ltd is not authorised to give investment advice.   Investment in the ICVC funds can only be made on the basis of the current Prospectus, Supplementary Information Document and relevant Key Investor Information Document.  These are available on our website

SVM Asset Management Ltd is authorised and regulated by the Financial Conduct Authority.  Registered address: 7 Castle Street, Edinburgh, EH2 3AH.  SVM Asset Management Ltd is the Authorised Corporate Director of SVM Funds ICVC.